Nirmatrelvir/Ritonavir/Remdesivir
Nirmatrelvir+ritonavir/tacrolimus
Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Molnupiravir/nirmatrelvir+ritonavir/remdesivir
Nirmatrelvir+ritonavir/Tacrolimus interaction